09/17/2025 08:00
ISN® Partners with Esso Exploration Angola Limited to Advance Contractor Management

ISN, the global leader in contractor and supplier information management services, announced the expansion of ISNetworld to Esso Exploration Angola Limited, an ExxonMobil affiliate, specialized in oil exploration and production. Through this collaboration, ISN will support Esso Angola in streamlining contractor management and oversight, meeting local compliance requirements, and increasing visibility into worker-level training and competency. “ExxonMobil has been a trusted partner of ISN for ...

08/31/2025 09:15
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card...

09/08/2025 04:05
Hidetaka Kokubu Appointed as Head of Japan at Xsolla

Xsolla, a global leader in video game commerce (CEO: Chris Hewish, HQ: Los Angeles, USA), is pleased to announce the appointment of Eiko Kokubun as Head of Japan, effective September 8, to further strengthen support for Japanese game companies seeking global expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250907348708/en/(Graphic: Xsolla) Prior to joining Xsolla, Kokubun held key leadership roles in both domestic and inter...

09/11/2025 13:05
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s Lasker~DeBakey Clinical Medical Research Award for his role “in the development of a novel, life-saving treatment for cystic fibrosis (CF) — namely, a triple-drug combination therapy, TRIKAFTA®, that has helped countless people with this genetic disease.” Dr. Negulescu is one of three awardees, alongside Jesús (Tito) González, a former ...